MedTrace Logo

Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia

NCT03597841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 278

Last updated 2019-07-24

No results posted yet for this study

Summary

Carbapenem-resistant Klebsiella pneumonia (CRKp) blood stream infections (BSI) cause substantial mortality among hospitalized patients. Treatment options for CRKp infections are limited and increasing resistance rates to few available drugs, i.e., colistin, is a big concern. This prospective multicenter observational study is designed to describe clinical characteristics and outcomes of patients with CRKp bacteremia in an oxacillinase-48 (OXA-48) endemic country to define predictors of mortality with a focus on the impact of mono versus combination therapies on mortality. The study will also investigate risk factors associated with colistin-resistant CRKp BSI.

Conditions

  • Klebsiella Pneumonia
  • Bacteremia

Interventions

DRUG

Combination therapy

Patients who are given combination therapy will be allocated to this group.

Sponsors & Collaborators

  • Koç University

    lead OTHER

Principal Investigators

  • Burcu Isler, MD · Sisli Hamidiye Etfal Training and Research Hospital

  • Önder Ergönül, MD · Koç University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2019-06-25
Completion
2019-07-22

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03597841 on ClinicalTrials.gov